文献速递先天性心脏病外科心外重症与机械循环支持

Scandiatransplant地区38年儿童心脏移植多国观察研究

Pediatric heart transplantation within the Scandiatransplant region-a multinational observational study spanning 38 years.
PubMed 文献 · J Heart Lung Transplant · 2025-06-05

该研究基于Scandiatransplant注册登记,分析1986至2023年38年间597例<18岁儿童心脏移植候选者的数量趋势、病因与结局;461例(77.2%)接受移植,候补死亡率从22.8%降至6.8%,移植后10年生存率78.0%、30年生存率51.4%。

要点

  • 候补死亡率从ERA I的22.8%降至ERA III的6.8%,等待时间延长但撤除频率稳定。
  • ABO不合移植从1.0%增至8.8%,心室辅助装置移植从6.6%增至19.9%。
  • 先天性心脏病病因者移植后生存劣于心肌病者,移植后10年生存率78.0%。

核心结论

  • Scandiatransplant地区儿童心脏移植数量低但随时间增加,候补死亡率显著下降,移植后结局改善不明显,可能因该地区首批移植短期结局优异。

研究设计与样本

  • 基于Scandiatransplant注册登记的多国观察性研究,纳入1986年1月1日至2023年12月31日列队等待心脏移植的<18岁儿童597例,按列队年代分为ERA I(1986-1998)、ERA II(1999-2011)和ERA III(2012-2023)。

主要发现

  • 597例列队儿童中461例(77.2%)接受心脏移植,区域移植发生率为4.0/100,000活产,所有中心年移植量中位数<4例。
  • 6.5%在<1岁时接受移植,候补时间随时间延长,撤除频率稳定,候补死亡率从ERA I的22.8%降至ERA III的6.8%。
  • 列队与移植诊断分布各年代无差异,ABO不合移植从ERA I的1.0%增至ERA III的8.8%,心室辅助装置移植从6.6%增至19.9%。
  • 移植后10年生存率78.0%、30年生存率51.4%,先天性心脏病病因者生存劣于心肌病者,列队年代是候补死亡率的决定因素而非移植后生存。

临床怎么用

  • 关注候补死亡率随时间下降的趋势,优化等待期管理。
  • 重视先天性心脏病病因儿童移植后生存较差,加强术后随访。
  • ABO不合移植和心室辅助装置桥接比例增加,需相应调整围术期策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thirty-eight years of pediatric heart transplantation (pHTx) within the Scandiatransplant organization were analyzed to describe volume trends, regional prevalence, underlying etiologies, and outcomes following listing and pHTx. METHODS: Children <18 years listed for pHTx from January 1st 1986 to December 31st 2023 were identified in the Scandiatransplant registry. The cohort was split into groups based on the era of listing (ERA I; 1986-1998, ERA II; 1999-2011, and ERA III; 2012-2023). RESULTS: A total of 597 children were listed and 461 (77.2%) reached pHTx. The regional incidence of pHTx was 4.0 per 100,000 live births. All centers performed a median of <4 pHTx per year. 6.5% were transplanted at <1 year of age. Waiting list duration increased over time, withdrawal frequency remained stable, and listing mortality decreased from 22.8% in ERA I to 6.8% in ERA III. The distribution of listing and transplant diagnoses were not different between eras. ABO-incompatible transplants increased over time, from 1.0% in ERA I to 8.8% in ERA III, as did transplant from ventricular assist devices (6.6% in ERA I, 19.9% in ERA III). Post-transplant survival was 78.0% at 10 years and 51.4% at 30 years. Survival was worse in patients with an etiology of congenital heart disease compared with cardiomyopathies. Era of listing was a determinant of listing mortality but not of post-transplant survival. CONCLUSIONS: Numbers of pHTx in the Scandiatransplant region are low but have increased with time. There has been a significant decrease in waiting list mortality over time, whereas improvements in post-pHTx outcomes have been less evident, most likely due to excellent short-term outcomes for the first graft recipients in the region.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. van der Have O, Tran-Lundmark K, Wåhlander H, et al. Pediatric heart transplantation within the Scandiatransplant region-a multinational observational study spanning 38 years. J Heart Lung Transplant. 2025. PMID: 40482845. doi:10.1016/j.healun.2025.05.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。